Subcutaneous amivantamab received accelerated approval for recurrent or metastatic head and neck cancer after platinum chemotherapy and immunotherapy
The FDA granted accelerated approval to subcutaneous amivantamab for recurrent or metastatic head and neck squamous cell carcinoma after prior ...
Get the app